Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026)

Amneal Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$59.1 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 50.78% year-over-year to -$59.1 million in Q1 2026; TTM through Mar 2026 was -$51.4 million, a 77.43% increase from a year earlier, with the FY2025 full-year figure at -$31.5 million, up 85.11% from the prior year.
• Cash from Financing Activities eased to -$59.1 million in Q1 2026 per AMRX's latest filing, from -$10.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $59.4 million in Q3 2025 and bottomed at -$100.8 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$39.2 million (2025), against an average of -$36.6 million.
• Across the five-year window, Cash from Financing Activities sank 354.87% in 2023 and jumped 164.37% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$22.2 million in 2022, then tumbled by 354.87% to -$100.8 million in 2023, then surged by 39.3% to -$61.2 million in 2024, then surged by 83.47% to -$10.1 million in 2025, then slumped by 483.55% to -$59.1 million in 2026.
• Per Business Quant, the three latest AMRX Cash from Financing Activities figures stand at -$59.1 million (Q1 2026), -$10.1 million (Q4 2025), and $59.4 million (Q3 2025).